|
1
|
Couri T and Pillai A: Goals and targets
for personalized therapy for HCC. Hepatol Int. 13:125–137. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chakraborty E and Sarkar D: Emerging
therapies for hepatocellular carcinoma (HCC). Cancers (Basel).
14:27982022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crocetti L, Bargellini I and Cioni R:
Loco-regional treatment of HCC: Current status. Clin Radiol.
72:626–635. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kulik L and El-Serag HB: Epidemiology and
management of hepatocellular carcinoma. Gastroenterology.
156:477–491.e1. 2019. View Article : Google Scholar
|
|
5
|
De Stefano F, Chacon E, Turcios L, Marti F
and Gedaly R: Novel biomarkers in hepatocellular carcinoma. Dig
Liver Dis. 50:1115–1123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sayiner M, Golabi P and Younossi ZM:
Disease burden of hepatocellular carcinoma: A global perspective.
Dig Dis Sci. 64:910–917. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujiwara N, Friedman SL, Goossens N and
Hoshida Y: Risk factors and prevention of hepatocellular carcinoma
in the era of precision medicine. J Hepatol. 68:526–549. 2018.
View Article : Google Scholar :
|
|
8
|
Sahu SK, Chawla YK, Dhiman RK, Singh V,
Duseja A, Taneja S, Kalra N and Gorsi U: Rupture of hepatocellular
carcinoma: A review of literature. J Clin Exp Hepatol. 9:245–256.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sharma D and Mandal P: NAFLD: Genetics and
its clinical implications. Clin Res Hepatol Gastroenterol.
46:1020032022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah PA, Patil R and Harrison SA:
NAFLD-related hepatocellular carcinoma: The growing challenge.
Hepatology. 77:323–338. 2023. View Article : Google Scholar
|
|
11
|
Popovic D, Vucic D and Dikic I:
Ubiquitination in disease pathogenesis and treatment. Nat Med.
20:1242–1253. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mansour MA: Ubiquitination: Friend and foe
in cancer. Int J Biochem Cell Biol. 101:80–93. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
van Wijk SJ, Fulda S, Dikic I and
Heilemann M: Visualizing ubiquitination in mammalian cells. EMBO
Rep. 20:e465202019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Komander D: The emerging complexity of
protein ubiquitination. Biochem Soc Trans. 37:937–953. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang Z, Jiang W, Mao M, Zhao J, Chen J and
Cheng N: Deubiquitinase USP35 modulates ferroptosis in lung cancer
via targeting ferroportin. Clin Transl Med. 11:e3902021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang J, Chen Y, Chen X, Zhang W, Zhao L,
Weng L, Tian H, Wu Z, Tan X, Ge X, et al: Deubiquitinase USP35
restrains STING-mediated interferon signaling in ovarian cancer.
Cell Death Differ. 28:139–155. 2021. View Article : Google Scholar :
|
|
17
|
Zhong Q, Wang Z, Kang H and Wu R:
Molecular mechanism of FBXW7-mediated ubiquitination modification
in nasopharyngeal carcinoma cell proliferation in vitro and in
vivo. Pathol Res Pract. 244:1540562023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar :
|
|
19
|
Beyoğlu D and Idle JR: The metabolomic
window into hepatobiliary disease. J Hepatol. 59:842–858. 2013.
View Article : Google Scholar
|
|
20
|
Leznicki P, Natarajan J, Bader G, Spevak
W, Schlattl A, Abdul Rehman SA, Pathak D, Weidlich S, Zoephel A,
Bordone MC, et al: Expansion of DUB functionality generated by
alternative isoforms-USP35, a case study. J Cell Sci.
131:jcs2127532018. View Article : Google Scholar
|
|
21
|
Zhang Z, Deng X, Liu Y, Liu Y, Sun L and
Chen F: PKM2, function and expression and regulation. Cell Biosci.
9:522019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sun T, Liu Z and Yang Q: The role of
ubiquitination and deubiquitination in cancer metabolism. Mol
Cancer. 19:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y and Deng J:
Ubiquitination-deubiquitination in the Hippo signaling pathway
(review). Oncol Rep. 41:1455–1475. 2019.PubMed/NCBI
|
|
24
|
Cao J, Wu D, Wu G, Wang Y, Ren T, Wang Y,
Lv Y, Sun W, Wang J, Qian C, et al: USP35, regulated by estrogen
and AKT, promotes breast tumorigenesis by stabilizing and enhancing
transcriptional activity of estrogen receptor α. Cell Death Dis.
12:6192021. View Article : Google Scholar
|
|
25
|
Wang W, Wang M, Xiao Y, Wang Y, Ma L, Guo
L, Wu X, Lin X and Zhang P: USP35 mitigates endoplasmic reticulum
stress-induced apoptosis by stabilizing RRBP1 in non-small cell
lung cancer. Mol Oncol. 16:1572–1590. 2022. View Article : Google Scholar
|
|
26
|
Dong X, Liu Z, Zhang E, Zhang P, Wang Y,
Hang J and Li Q: USP39 promotes tumorigenesis by stabilizing and
deubiquitinating SP1 protein in hepatocellular carcinoma. Cell
Signal. 85:1100682021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye
S, Cao J, Ying M, Dai X, Gai R, et al: Deubiquitinating enzyme
USP10 promotes hepatocellular carcinoma metastasis through
deubiquitinating and stabilizing Smad4 protein. Mol Oncol.
14:197–210. 2020. View Article : Google Scholar :
|
|
28
|
Liberti MV and Locasale JW: The Warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pascale RM, Calvisi DF, Simile MM, Feo CF
and Feo F: The Warburg effect 97 years after its discovery. Cancers
(Basel). 12:28192020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Israelsen WJ and Vander Heiden MG:
Pyruvate kinase: Function, regulation and role in cancer. Semin
Cell Dev Biol. 43:43–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grant MM: Pyruvate kinase, inflammation
and periodontal disease. Pathogens. 10:7842021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zahra K, Dey T, Ashish, Mishra SP and
Pandey U: Pyruvate kinase M2 and cancer: The role of PKM2 in
promoting tumorigenesis. Front Oncol. 10:1592020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang W, Xia Y, Hawke D, Li X, Liang J,
Xing D, Aldape K, Hunter T, Alfred Yung WK and Lu Z: PKM2
phosphorylates histone H3 and promotes gene transcription and
tumorigenesis. Cell. 150:685–696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang J, Cao R, Wang X, Zhang Y, Wang P,
Gao H, Li C, Yang F, Zeng R, Wei P, et al: Mitochondrial PKM2
regulates oxidative stress-induced apoptosis by stabilizing Bcl2.
Cell Res. 27:329–351. 2017. View Article : Google Scholar :
|
|
35
|
Chen D, Wang Y, Lu R, Jiang X, Chen X,
Meng N, Chen M, Xie S and Yan GR: E3 ligase ZFP91 inhibits
hepatocellular carcinoma metabolism reprogramming by regulating PKM
splicing. Theranostics. 10:8558–8572. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang W, Wang B, Yu Q, Liu T, Li T, Tian T,
Jin A, Ding L, Chen W, Wang H, et al: ARHGAP24 represses β-catenin
transactivation-induced invasiveness in hepatocellular carcinoma
mainly by acting as a GTPase-independent scaffold. Theranostics.
12:6189–6206. 2020. View Article : Google Scholar
|
